The corporate mentioned that the trials will probably be performed on as many as 2500 Covid-19 patients affected by delicate and reasonable signs. The drug will probably be administered for a interval of 5 days to the volunteers.
“As per the medical trial protocols permitted, whole of 2500 topics in each delicate and reasonable Covid-19 will probably be randomised within the research in a 1:1 ratio for Molnupiravir with commonplace supportive care or standalone commonplace supportive care. The remedy period is a most of 5 days and the overall research period will probably be most for 29 days from randomisation,” the corporate mentioned.
Molnupiravir is an experimental anti-viral drug developed for influenza and is now being repurposed for Covid-19.